Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Anova Innovation Limited
National Cancer Institute (NCI)
NRG Oncology
Actuate Therapeutics Inc.
UNC Lineberger Comprehensive Cancer Center
SWOG Cancer Research Network
Eastern Cooperative Oncology Group
ImmunityBio, Inc.
Eli Lilly and Company
Engeneic Pty Limited
Ohio State University Comprehensive Cancer Center
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Emory University
National Health Research Institutes, Taiwan
Ascentage Pharma Group Inc.
Alliance for Clinical Trials in Oncology
OHSU Knight Cancer Institute
Mayo Clinic
Emory University
Mayo Clinic
Tyligand Pharmaceuticals (Suzhou) Limited
University Health Network, Toronto
Barts & The London NHS Trust
University of Southern California
Thomas Jefferson University
City of Hope Medical Center
Emory University
Trishula Therapeutics, Inc.
University of Colorado, Denver
AHS Cancer Control Alberta
Columbia University
Georgetown University
German Cancer Research Center
THERABIONIC INC.
Aalborg University Hospital
Purple Biotech Ltd.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Australasian Gastro-Intestinal Trials Group
OHSU Knight Cancer Institute
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Shanghai Zhongshan Hospital
University Hospital, Geneva
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Fudan University
RenJi Hospital
Fudan University
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute